Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma

Main Article Content

Xufeng Zhang
Junfu Wang
Yanhua Cao
Kalin Li
Chao Sun
Wen Jiang
Qian Xin
Jue Wang
Tonggang Qi
Shuangde Liu
Yun Luan

Keywords

clear cell carcinoma, epithelial–mesenchymal transition, ligustrazine, migration, proliferation

Abstract

Ligustrazine is a Chinese herb (Chuanxiong) approved for use as a medical drug in China. Recent evidence suggests that ligustrazine has promising antitumor properties. Our preliminary results showed that ligustrazine could inhibit the growth of human renal cell carcinoma (RCC) cell lines. However, the complicated molecular mechanism has not been fully revealed. Therefore, the purpose of this study to investigate the mechanism of ligustrazine resistance in human RCC cells. Cell proliferation, migration, invasion, and colony-formation ability of RCC cells A498 were detected by MTT assay, clonal formation rates, and transwell chamber assay in vitro. The expression of epithelial–mesenchymal transition (EMT)–related proteins were analyzed using western blot test. The effect of ligustrazine on the growth of A498 cells in nude mice was investigated in vivo. Our results showed that ligustrazine could significantly inhibit the proliferation, migration, and invasion of A498 both in vivo and vitro. Western blot analysis showed that the expressions of EMT-related, N-cadherin, snail, and slug proteins were significantly decreased in A498 in the ligustrazine treatment group. This study indicated that ligustrazine could significantly inhibit the malignant biological behaviors of RCC cell lines, possibly by inhibiting the EMT process.

Abstract 455 | PDF Downloads 896 HTML Downloads 66 XML Downloads 14

References

1. Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 2014;11(9):517–25. 10.1038/nrurol.2014.194

2. Linehan WM, Ricketts CJ. The cancer genome atlas of renal cell carcinoma: Findings and clinical implications. Nat Rev Urol. 2019;16(9):539–52. 10.1038/s41585-019-0211-5

3. Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C, Czarnecka AM. Choosing the right cell line for renal cell cancer research. Mol Cancer. 2016;15(1):83. 10.1186/s12943-016-0565-8

4. Siva S, Kothari G, Muacevic A, Louie AV, Slotman BJ, Teh BS, et al. Radiotherapy for renal cell carcinoma: Renaissance of an overlooked approach. Nat Rev Urol. 2017;14(9):549–63. 10.1038/nrurol.2017.87

5. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96. 10.1038/nrm3758

6. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. 10.1038/s41580-018-0080-4

7. Zhang N, Ng AS, Cai S, Li Q, Yang L, Kerr D. Novel therapeutic strategies: Targeting epithelial-mesenchymal transition in colorectal cancer. Lancet Oncol. 2021;22(8):e358–68. 10.1016/S1470-2045(21)00343-0

8. Saitoh M. Involvement of partial EMT in cancer progression. J Biochem. 2018;164(4):257–64. 10.1093/jb/mvy047

9. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–29. 10.1038/nrclinonc.2017.44

10. Zhao T, Fu Y, Sun H, Liu X. Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia. IUBMB Life. 2018;70(1):60–70. 10.1002/iub.1704

11. Ma X, Ruan Q, Ji X, Yang J, Peng H. Ligustrazine alleviates cyclophosphamide-induced hepatotoxicity via the inhibition of Txnip/Trx/NF-κB pathway. Life Sci. 2021;274:119331. 10.1016/j.lfs.2021.119331

12. Li H, Yang M. Ligustrazine activate the PPAR-γ pathway and play a protective role in vascular calcification. Vascular. 2021;20:17085381211051477. 10.1177/17085381211051477

13. Du HY, Wang R, Li JL, Luo H, Xie XY, Yan R, et al. Ligustrazine induces viability, suppresses apoptosis and autophagy of retinal ganglion cells with ischemia/reperfusion injury through the PI3K/Akt/mTOR signaling pathway. Bioengineered. 2021;12(1):507–15. 10.1080/21655979.2021.1880060

14. Zhang C, Guan D, Jiang M, Liang C, Li L, Zhao N, et al. Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: Prediction with network pharmacology and validation in a clinical trial. Chin Med. 2019;14:26. 10.1186/s13020-019-0247-8

15. Bukhari SNA, Alotaibi NH, Ahmad W, Alharbi KS, Abdelgawad MA, Al-Sanea MM, et al. Evaluation of ligustrazine-based synthetic compounds for their antiproliferative effects. Med Chem. 2021;17(9):956–62. 10.2174/1573406416666200905125038

16. Bian Y, Yang L, Sheng W, Li Z, Xu Y, Li W, et al. Ligustrazine induces the colorectal cancer cells apoptosis via p53-dependent mitochondrial pathway and cell cycle arrest at the G0/G1 phase. Ann Palliat Med. 2021;10(2):1578–88. 10.21037/apm-20-288

17. Zhang H, Ding S, Xia L. Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211. Biosci Rep. 2021;41(1):BSR20200199. 10.1042/BSR20200199

18. Qian J, Xu Z, Zhu P, Meng C, Liu Y, Shan W, et al. Derivative of piperlongumine and ligustrazine as a potential thioredoxin reductase inhibitor in drug-resistant hepatocellular carcinoma. J Nat Prod. 2021;84(12):3161–8. 10.1021/acs.jnatprod.1c00618

19. Luan Y, Liu J, Liu X, Xue X, Kong F, Sun C, et al. Tetramethypyrazine inhibits renal cell carcinoma cells through inhibition of NKG2D signaling pathways. Int J Oncol. 2016;49(4):1704–12. 10.3892/ijo.2016.3670

20. Jia Y, Wang Z, Zang A, Jiao S, Chen S, Fu Y. Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling. Int J Oncol. 2016;48(5):2079–86. 10.3892/ijo.2016.3443

21. Kim M, Kim SO, Lee M, Lee JH, Jung WS, Moon SK, et al. Tetramethylpyrazine, a natural alkaloid, attenuates pro-inflammatory mediators induced by amyloid β and interferon-γ in rat brain microglia. Eur J Pharmacol. 2014;740:504–11. 10.1016/j.ejphar.2014.06.037

22. Yu T, Guo X, Zhang Z, Liu R, Zou L, Fu J, et al. Meta-analysis of the clinical effectiveness and safety of ligustrazine in cerebral infarction. Evid Based Complement Alternat Med. 2016;2016:3595946. 10.1155/2016/3595946

23. Tang SL, Gao YL, He H. Influence of ligustrazine hydrochloride injection combined Buyang Huanwu Tang to intervention on blood viscosity and coagulation factor with acute cerebral infarction patients. Chin J ETMF. 2015;21:161–4.

24. Wolf MM, Kimryn Rathmell W, Beckermann KE. Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene. 2020;39(17):3413–26. 10.1038/s41388-020-1234-3

25. Trebinska-Stryjewska A, Swiech O, Opuchlik LJ, Grzybowska EA, Bilewicz R. Impact of medium pH on DOX toxicity toward HeLa and A498 cell lines. ACS Omega. 2020;5(14):7979–86. 10.1021/acsomega.9b04479

26. Cao YH, Xue X, Li J, Cao PH, Luan Y. Inhibitory effect of ligustrazine on renal clear cell carcinoma and its mechanism. 2019;20(8):2477–2482. 10.3969/j.issn.1000-484X

27. Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, et al. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol. 2013;190(3):1059–68. 10.1016/j.juro.2013.02.089

28. Xie D, Li J, Wei S, Qi P, Ji H, Su J, et al. Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression. Mol Cell Probes. 2020;53:101608. 10.1016/j.mcp.2020.101608

29. Wang X, Xiao Y, Li S, Yan Z, Luo G. CORO6 promotes cell growth and invasion of clear cell renal cell carcinoma via activation of WNT signaling. Front Cell Dev Biol. 2021; 9:647301. 10.3389/fcell.2021.647301

30. Khan MI, Sobocińska AA, Brodaczewska KK, Zielniok K, Gajewska M, Kieda C, et al. Involvement of the CB(2) cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC Cancer. 2018;18(1):583. 10.1186/s12885-018-4496-1